GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » Price-to-Tangible-Book

ArriVent BioPharma (ArriVent BioPharma) Price-to-Tangible-Book : 1.97 (As of Jun. 06, 2024)


View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma Price-to-Tangible-Book?

As of today (2024-06-06), ArriVent BioPharma's share price is $18.67. ArriVent BioPharma's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $9.49. Hence, ArriVent BioPharma's Price to Tangible Book Ratio of today is 1.97.

The historical rank and industry rank for ArriVent BioPharma's Price-to-Tangible-Book or its related term are showing as below:

AVBP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.88   Med: 1.88   Max: 1.97
Current: 1.97

During the past 3 years, ArriVent BioPharma's highest Price to Tangible Book Ratio was 1.97. The lowest was 1.88. And the median was 1.88.

AVBP's Price-to-Tangible-Book is ranked better than
65.93% of 1221 companies
in the Biotechnology industry
Industry Median: 2.78 vs AVBP: 1.97

A closely related ratio is called PB Ratio. As of today, ArriVent BioPharma's share price is $18.67. ArriVent BioPharma's Book Value per Sharefor the quarter that ended in Mar. 2024 was $9.49. Hence, ArriVent BioPharma's P/B Ratio of today is 1.97.


ArriVent BioPharma Price-to-Tangible-Book Historical Data

The historical data trend for ArriVent BioPharma's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArriVent BioPharma Price-to-Tangible-Book Chart

ArriVent BioPharma Annual Data
Trend Dec21 Dec22 Dec23
Price-to-Tangible-Book
- - -

ArriVent BioPharma Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only - - - - 1.88

Competitive Comparison of ArriVent BioPharma's Price-to-Tangible-Book

For the Biotechnology subindustry, ArriVent BioPharma's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ArriVent BioPharma's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ArriVent BioPharma's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where ArriVent BioPharma's Price-to-Tangible-Book falls into.



ArriVent BioPharma Price-to-Tangible-Book Calculation

ArriVent BioPharma's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=18.67/9.486
=1.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


ArriVent BioPharma Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of ArriVent BioPharma's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


ArriVent BioPharma (ArriVent BioPharma) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. They seek to utilize our team's deep drug development experience to maximize the potential of our lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

ArriVent BioPharma (ArriVent BioPharma) Headlines

From GuruFocus